ABOUT US
Our proprietary platform is an automated WGS pipeline coupled with a bioinformatics-powered digital solution that reads and translates a patient’s whole genome sequence and provides medically meaningful insights.
Our company was founded in January 2020 by co-founders Young Seok Ju and Jeong Seok Lee who recognized the need for academic-level whole-genome data to be useable in real-world cancer patient treatment. They assembled a team of trailblazers in the field of precision medicine with the shared goal of making genomic data/insights accessible to all. We are a growing team of experts in data science, biology, and medicine.
We have built on the strong academic foundation of our leadership. Young Seok Ju has pioneered whole genome sequencing, being a core member of the Cancer Genome Project at the Wellcome Trust Sanger Institute. He reported the first whole genome sequence analysis of a Korean individual (Nature, 2009). Genome Insight continues this legacy by sharing significant data regularly.
Began analysis of Illumina Platform
First successful WGS analysis of a Korean individual
WGS-based investigation of gene copy number variation
WGS-WTS simultaneous analysis
Identification of non-smoker LC gene KIF5B-RET target
Pan-cancer WGS mitochondria analysis
WGS-based identification of mtDNA nuclear transfer
Revealed early somatic mosaicism using WGS
To capitalize on an as-yet nascent market for cat photos.
Rare cancer WGS mutation
Identification of LC WGS clonal evolution
Non-smoker LC WGS
Rare immune disorder WGS mosaicism variant analysis; joint research with NIH
3,000 cancer WGS mitochondria analysis
K-CDC COVID-19 multiomics project (Total $6M/8mo) WGS service contract
COVID-19 Single cell transcriptome analysis
COVID-19 infection model establishment & variant analysis
WGS-based investigation of human single cell mosaicism
